• 1
    Powell WC, Knox JD, Navre M, Grogan TM, Kittelson J, Nagle RB, et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 1993; 53: 41722.
  • 2
    Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 126070.
  • 3
    Lochter A, Sternlicht MD, Werb Z, Bissell MJ. The significance of matrix metalloproteinases during early stages of tumor progression. Ann N Y Acad Sci 1998; 857: 18093.
  • 4
    Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 113549.
  • 5
    Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000; 14: 212333.
  • 6
    Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999; 99: 8192.
  • 7
    Ito A, Mukaiyama A, Itoh Y, Nagase H, Thogersen IB, Enghild JJ, et al. Degradation of interleukin-1 beta by matrix metalloproteinases. J Biol Chem 1996; 27: 1465760.
  • 8
    Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, Mayouf SA, et al. Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat Genet 2001; 28: 2615.
  • 9
    Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J 1997; 322: 80914.
  • 10
    Sato T, Foged NT, Delaisse JM. The migration of purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors. J Bone Miner Res 1998; 13: 5966.
  • 11
    Schedin P, Strange R, Mitrenga T, Wolfe P, Kaeck M. Fibronectin fragments induce MMP activity in mouse mammary epithelial cells: evidence for a role in mammary tissue remodeling. J Cell Sci 2000; 113: 795806.
  • 12
    Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93: 41122.
  • 13
    Hagmann W, Lark MW, Becker J. Inhibition of matrix metalloproteinases. Annu Rep Med Chem 1996; 31: 23140.
  • 14
    Summers J, Davidsen S. Matrix metalloproteinase inhibitors and cancer. Annu Rep Med Chem 1998; 33: 13140.
  • 15
    Sykes AP, Bhogal R, Brampton C, Chander C, Whelan C, Parsons ME, et al. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther 1999; 13: 153542.
  • 16
    Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 1999; 878: 22835.
  • 17
    Hutchinson JW, Tierney GM, Parsons SL, Davis TR. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br 1998; 80: 9078.
  • 18
    Tierney GM, Griffin NR, Stuart RC, Kasem H, Lynch KP, Lury JT, et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 1999; 35: 5638.
  • 19
    Beckett RP, Whittaker M, Miller A, Martin FM. The compound N′- [2,2-dimethyl-1S-(pyridin-2-ylcarbamoyl)-propyl]-N4-hydroxy-2R-isobutyl-3S-methoxy-succinamide is a matrix metalloproteinase inhibitor. International Publication Number WO 99/25693 (British Biotech Pharmaceuticals Ltd.), 1997.
  • 20
    Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998; 4: 11019.
  • 21
    Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998; 16: 21506.
  • 22
    Levitt NC, Eskins F, Propper DJ. A phase one pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor. Proceedings of 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 16–19; Los Angeles (CA); 17: 213A.
  • 23
    Wilding G, Small E, Collier M. A phase I pharmacokinetic evaluation of the matrix metalloproteinase inhibitor AG3340 in combination with mitoxantrone and prednisone in patients with advanced prostate cancer. Proceedings of 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA); 18: 323A.
  • 24
    Millar A. 360 patient meta-analysis of studies of marimastat: a novel matrix metalloproteinase inhibitor. Ann Oncol 1996; 7 Suppl 5: 123.
  • 25
    Heath EI, Grochow LB. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 2000; 59: 104355.
  • 26
    Wood ND, Aitken M, Harris S, Kitchener S, McClelland GR, Sharp S. The tolerability and pharmacokinetics of the cartilage protective agent (Ro32-3555) in healthy male volunteers. Br J Clin Pharmacol 1996; 42: 67677.
  • 27
    Barlaam B, Bird TG, Lambert-Van Der Brempt C, Campbell D, Foster SJ, Maciewicz R. New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. J Med Chem 1999; 42: 4890908.
  • 28
    Hasty KA, Reife RA, Kang AH, Stuart JM. The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum 1990; 33: 38897.
  • 29
    Stein-Picarella M, Ahrens D, Mase C, Golden H, Niedbala MJ. Localization and characterization of matrix metalloproteinase-9 in experimental rat adjuvant arthritis. Ann N Y Acad Sci 1994; 732: 4845.
  • 30
    Boyle DL, Kowaluk EA, Jarvis MF, Lee C-H, Bhagwat SS. Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis. J Pharmacol Exp Ther 2001; 296: 495500.
  • 31
    Lee ER, Murphy G, El-Alfy M, Davoli MA, Lamplugh L, Docherty AJ, et al. Active gelatinase B is identified by histozymography in the cartilage resorption sites of developing long bones. Dev Dyn 1999; 215: 190205.
  • 32
    Sasano Y, Zhu J-X, Tsubota M, Takahashi I, Onodera K, Mizoguchi I, et al. Gene expression of MMP8 and MMP13 during embryonic development of bone and cartilage in the rat mandible and hind limb. J Histochem Cytochem 2002; 50: 32532.
  • 33
    Alvarez J, Balbin M, Santos F, Fernandez M, Ferrando S, Lopes JM. Different bone growth rates are associated with changes in the expression pattern of types II and X collagens and collagenase 3 in proximal growth plates of the rat tibia. J Bone Miner Res 2000; 15: 8294.
  • 34
    Alvarez J, Balbin M, Fernandez M, Lopez JM. Collagen metabolism is markedly altered in the hypertrophic cartilage of growth plates from rats with growth impairment secondary to chronic renal failure. J Bone Miner Res 2001; 16: 51124.
  • 35
    Filanti C, Dickson GR, Di Martino D, Ulivi V, Sanguineti C, Romano P, et al. The expression of metalloproteinase-2, -9, and -14 and of tissue inhibitors-1 and -2 is developmentally modulated during osteogenesis in vitro, the mature osteoblastic phenotype expressing metalloproteinase-14. J Bone Miner Res 2000; 15: 215468.
  • 36
    Maeda S, Dean DD, Gomez R, Schwartz Z, Boyan BD. The first stage of transforming growth factor beta1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3). Calcif Tissue Int 2002; 70: 5465.
  • 37
    Zhou Z, Apte SS, Soininen R, Cao R, Baaklini GY, Rauser RW, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase. Proc Natl Acad Sci U S A 2000: 97: 40527.